MALIGNANIT MELANOMA

Irving M. Ariel

MALIGNANT MELANOMA

Irving M. Ariel
M.D., F.A.C.S., M.S. (SURGERY), M.S. (RADIOLOGY)

Professor of Clinical Surgery

New York Medical College New York, New York

State University of New York at Stony Brook Stony Brook, New York

Attending Surgeon

Long Island Jewish Hospital New Hyde Park, New York

Cabrini Medical Center New York, New York



APPLETON-CENTURY-CROFTS/New York

Copyright © 1981 by APPLETON-CENTURY-CROFTS A Publishing Division of Prentice-Hall, Inc.

All rights reserved. This book, or any parts thereof, may not be used or reproduced in any manner without written permission. For information, address Appleton-Century-Crofts, 292 Madison Avenue, New York, N.Y. 10017.

81 82 83 84 85 / 10 9 8 7 6 5 4 3 2 1

Prentice-Hall International, Inc., London Prentice-Hall of Australia, Pty. Ltd., Sydney Prentice-Hall of India Private Limited, New Delhi Prentice-Hall of Japan, Inc., Tokyo Prentice-Hall of Southeast Asia (Pte.) Ltd., Singapore Whitehall Books Ltd., Wellington, New Zealand

Library of Congress Cataloging in Publication Data Main entry under title:

Malignant melanoma.

Bibliography.
Includes index.

1. Melanoma. I. Ariel, Irving M. [DNLM:

1. Melanoma. QZ 200 M2495]

RC280.S5M35 616.99'4 ISBN 0-8385-6114-4

81-485 AACR1

Cover design: Gloria Moyer Text design: Alan Gold

PRINTED IN THE UNITED STATES OF AMERICA

Dedicated to the Memory of Dr. George T. Pack (1898–1969) for his outstanding contributions to clinical cancer, particularly malignant melanoma

and

Harold S. Brady (1909–1976) for his dedicated devotion to medical research and education.

CONTRIBUTORS

Rajendra M. Agrawal, M.D. Chief Resident in Surgery New York Infirmary New York, New York

Irving M. Ariel, M.D., F.A.C.S.,
M.S. (SURGERY), M.S. (RADIOLOGY)

Professor of Clinical Surgery
New York Medical College
New York, New York
State University of New York at Stony
Brook
Stony Brook, New York
Attending Surgeon
Long Island Jewish Hospital
New Hyde Park, New York
Cabrini Medical Center
New York, New York

Myron Arlen, M.D., F.A.C.S. Clinical Associate Professor of Surgery Downstate Medical Center; Chief of Surgical Oncology Brookdale Hospital Medical Center New York, New York

Philip W. Banda, Ph.D.
Department of Dermatology
University of California
San Francisco, California

Graeme L. Beardmore, M.B., B.S., D.D.M., F.A.C.D. Honorary Research Fellow Queensland Melanoma Project Princess Alexandra Hospital Brisbane, Queensland, Australia William H. Beierwaltes, A.B., M.D. Professor, Physician-In-Charge Department of Internal Medicine Division of Nuclear Medicine Ann Arbor, Michigan

Alexander Breslow, M.D.
Head of the Surgical Pathology Division
Professor of Pathology
George Washington University Medical
Center
Washington, D.C.

Arthur S. Caron, M.D., F.A.C.S.
Clinical Assistant Surgeon of Breast
Service
Memorial Sloan Kettering Cancer
Center;
Attending Surgeon
Doctors Hospital
New York, New York

John Conley, M.D.
Professor of Clinical Otolaryngology
(Emeritus)
Columbia Presbyterian Medical Center;
Chief, Head and Neck Surgery
St. Vincent's Hospital and Pack Medical
Foundation
New York, New York

Neville C. Davis, M.D., HON. D.S., F.R.C.S., F.R.A.C.S., F.A.C.S. Co-ordinator, Queensland Melanoma Project Princess Alexandra Hospital Brisbane, Queensland, Australia Laurence Desjardins, M.D.

Fellow in Ophthalmic Oncology Edward S. Harkness Eye Institute of Columbia Presbyterian Medical Center

Department of Ophthalmology of the Columbia University of Physicians and Surgeons of New York City, New York, New York

John M. Edwards, M.S., F.R.C.S.,

F.A.C.N.M.

Consultant Surgeon and Senior Lecturer St. Thomas' Hospital London, England

Mary Anne Fitzmaurice, M.S.

Department of Microbiology Pacific Northwest Research Foundation Seattle, Washington

Glenn W. Geelhoed, m.n. Associate Professor of Surgery George Washington University Medical Center

Washington, D.C.

Satinder T. Gill, M.D.

Chief of Nuclear Medicine Service Veterans Administration Medical Center Martinsburg, West Virginia

Stephen L. Gumport, M.D., F.A.C.S. Professor of Surgery Consultant, Division of Oncology Department of Surgery

New York University Medical Center New York, New York

Ronald C. Hamaker, M.D.

Assistant Professor Department of Otorhinolaryngology Indiana University School of Medicine Indianapolis, Indiana Matthew N. Harris, M.D., F.A.C.S.
Professor of Surgery
New York University School of
Medicine;
Director, Division of Oncology
Department of Surgery
New York University Medical Center
New York, New York

Ariel Hollinshead, Ph.D.

Professor of Medicine George Washington University College of Medicine Washington, D.C.

John Holt, B.Sc., Ph.D.

Lecturer in Numerial Analysis Department of Mathematics University of Queensland Brisbane, Queensland, Australia

Ira S. Jones, M.D.

Clinical Professor of Ophthalmology Columbia University College of Physicians and Surgeons; Attending Surgeon Edward S. Harkness Eye Institute of the Presbyterian Hospital New York, New York

John H. Little, M.B., B.S., D.P.H.,
D.C.P., F.R.C.Path., F.R.C.P.A.
Director of Pathology
Princess Alexandra Hospital
Brisbane, Queensland, Australia

G. Roderick McLeod, M.B., B.S.,

F.R.C.S.(Edin), F.R.C.S., F.R.A.C.S. Senior Research Fellow Queensland Melanoma Project Princess Alexandra Hospital Brisbane, Queensland, Australia Ruben Oropeza, M.D., F.A.C.S.
Assistant Professor in Surgery
Columbia University;
Assistant Clinical Professor in Surgery
Mount Sinai Medical School
New York, New York

Redmond L. Quinn, M.B., B.S., B.Sc., M.C.Path., F.R.C.P.A. Anatomical Pathologist Princess Alexandra Hospital Brisbane, Queensland, Australia

Vernon Riley, D.Sc.

Chairman, Department of Microbiology
Pacific Northwest Research Foundation;
Member, Fred Hutchinson Cancer
Research Center;
Professor (Adjunct)
Department of Rehabilitation Medicine
University of Washington School of
Medicine
Seattle, Washington

Joseph Scherrer, M.A.
Research Associate
Department of Surgery
Brookdale Hospital Medical Center
New York, New York

Darrel H. Spackman, Ph.D.

Department of Microbiology
Pacific Northwest Research Foundation;
Research Scientist
Fred Hutchinson Cancer Research
Center;
Associate Professor (Adjunct)
Department of Rehabilitation Medicine
University of Washington School of
Medicine
Seattle, Washington

Marianne Wolff, A.B., M.D.
Associate Professor of Clinical Surgical
Pathology
College of Physicians and Surgeons
Columbia University;
Associate Attending Surgical Pathologist
Presbyterian Hospital of the City
of New York
New York, New York

PREFACE

The magnificent melanocyte and the maleficent melanoma are discussed in this volume. The melanocyte present throughout most of the animal kingdom is a truly remarkable cell. Its protective function varies from instantaneous camouflage, as in the chameleon, to inherited pigmentary characteristics developed as part of the evolutionary development of a given species, to its production of protective pigmentary changes for protection as occurs by tanning in the human after exposure to solar radiation.

Although the number of melanocytes are more or less equal for the different races, the genetic transfer of the amount of pigmentary granules produced by these melanocytes has resulted in different skin coloration varying from the Caucasian to the Negro. The social implications of this melanocyte function are universally evident.

The melanocytes arise from the precursor melanoblast during embryonic development within the neural crest and migrate throughout the body (skin, mucous membrane, nervous system, eye, and other locations). All except those of the retinal pigment can undergo malignant transformation and form a malignant melanoma. The skin is the most frequent site. The actual number of melanocytes in a given individual or in different locations in the same individual does not seem to influence the formation of a melanoma. The amount of pigment produced, the eumelanins, do influence the development of malignancy. Darker-pigmented individuals have a much lower incidence of malignant melanoma (Chapter 2).

Just as the term *cancer* is meaningless inasmuch as certain lesions called *cancer* can be cured by conservative measures (basal cell carcinoma) whereas others spell a death sentence with the diagnosis, so the term melanoma is losing its sting as certain subdivisions of the generic term have different meanings. The clinician is deeply indebted to certain pathologists and dermatologists for their painstaking researches describing malignant melanoma as a multifaceted disease with subclassifications requiring different forms of treatment and having different prognoses. Some of these evolutionary changes in the natural history of melanoma have been published in the excellent book by W. E. Clark, Jr., Leonard I. Goldman, and Michael J. Mastrangelo, and also one by Alfred W. Kopf.

This volume focuses upon the diagnosis, treatment techniques, and accomplishments in curing malignant melanoma. Many of the chapters express the clinical story of patients with malignant melanoma treated by surgeons at the Pack Medical Group during the years between 1935 and 1972.

Although the classification of levels of invasion (Clark et al.) or thickness of the lesion (Breslow-Chapter 6) were not available during the study, the cases were classified as superficial or invasive. We do not consider level I as a metastasizing melanoma and it is not included in the presentation. Level III (Clark's classification) is somewhat ambiguous. Great strides have been made in staging, but strict adherence to mechanistic parameters may be too simplistic as the formation growth and spread of melanoma involve many metabolic interactions which include genetic, chronologic, sexual, hormonal, and immunologic factors. Considerations of the histologic, immunologic and other markers are necessary to define better the clinical conduct of a patient with malignant melanoma.

The vast majority of our patients during 1935 to 1972 suffered from infiltrating melanomas suggesting a late stage of involvement. The clinical climate is different now since earlier diagnoses are being made due to lay education and professional awareness.

This volume commences with general considerations discussing the role of the ubiqui-

tous mole and the iniquitous melanoma; discussions regarding the suggestive causes of melanoma; the universality, incidence, and epidemiology of malignant melanoma. Then Chapter 4 deals with the pathology of melanoma, written by a great student and authority on melanoma, Dr. Marianne Wolff. Drs. Myron Arlen, Ariel Hollinshead, and Joseph Scherrer in Chapter 8 discuss the strides rapidly being made in investigating how melanoma is influenced by the immune system of the host.

Besides the histologic characteristics of different melanomas with the identification of the juvenile melanoma (Spitz nevus) and the B.K. mole, certain biochemical markers illustrating metabolic pathways are discussed by Doctors Vernon Riley and Phillip Banda (Chapter 9).

Principles of clinical evaluation, prognostic indices, routes of lymphatic spread, and the dynamics of lymphatic spread are also discussed. The role of chemotherapy, endolymphatic isotope therapy, and the accomplishments of treating melanoma as a community disease in a location with the highest incidence of melanoma—Queensland, Australia—are presented.

Once a diagnosis of melanoma is established, definitive treatment often depends on the anatomic setting; in fact, melanoma in different locations will be referred to doctors of different specialties. The second section of the volume is presented according to the specific anatomic sites. Melanoma of the head and neck, including mucous membranes, are presented by Doctors Hamaker and Conley, largely from the Pack Medical Group series. Melanoma of the eye and orbit, an important site from the standpoint of etiology, therapy, and immunology, is discussed by Drs. Ira Jones and Laurence Desjardins, authorities in this field. The delay of 10 to 25 years for

metastases to present in the liver after enucleation of an eye melanoma evokes speculation regarding the immune mechanisms involved.

In later chapters, the trunk is divided into those melanomas arising from the thorax and those from the skin of the abdomen, because of the lymphatic vessels which are at risk.

Subungual melanomas are treated in a separate chapter stressing the clinical picture and treatment policies of this unique site for melanoma formation.

Melanomas arising at various rare sites are presented for the sake of completeness, such as those arising from the gastrointestinal tract, genitalia, and central nervous system.

The volume closes with a chapter describing the diagnosis of a pulmonary mass in a patient treated previously for melanoma and the conduct of treating such a patient.

There is an ebb and flow in the growth of melanoma and reaction of the host as evidenced by increased pigmentation and size (growth), redness (inflammation), interspacing white areas (host-reaction-destroying melanoma). There is an increased incidence of melanoma but a decrease in deaths as earlier diagnoses are made and adequate therapy instituted.

The authors paradoxically hope that the techniques herein described may soon become obsolete and that preventive early conservative treatment be instituted before the full malignancy of the lesion develops, preferably by instituting immune techniques in preventing and/or treating melanoma. In the meantime this volume offers techniques and accomplishments in treating the patient with infiltrating melanoma today. Further study is needed to define the best treatment for patients with superficial melanomas, level II (Clark), or less than 0.75 mm thickness (Breslow).

ACKNOWLEDGEMENTS

It is a dutiful pleasure to acknowledge with appreciation our indebtedness to the many authorities and their notable contributions which have made this book possible.

The superior medical illustrations contribute greatly to the value of the text. I express my gratitude to each of the medical illustrators and to our own medical photographer, Mr. Harry Weissfisch, for his cooperation in supplying excellent illustrations. I join with the other authors in acknowledging the generous cooperation of the many journals and publishers who freely permitted the use of graphic and statistical material. Specific acknowledgements are given throughout the text.

Our research assistants, Mrs. Brenda Lewy, Mrs. Ingegard Angerer, and Mr. Robert Ariel, have been most assiduous and competent in the assemblage of statistical and referential data for reporting.

Mrs. Pamela Bartle, our editorial associate, tirelessly typed complicated and sometimes unintelligible tapes into rough manuscripts from which the final copy was derived.

The following individuals or foundations have made contributions which were utilized

for the vast task of assembling the raw data into reportable manuscripts with the final assemblage of the complicated and complex variables into this coordinated text:

The Pack Medical Foundation
The Foundation for Clinical Research
The Harold S. Brady Cancer Research Fund
The Marilyn Fixman Memorial Cancer
Research Fund
The Benjamin Schwartz Foundation
The Janet K. Hetherington Fund
The Arnold and Muriel Rosen Cancer Fund
Mr. Philip Bornstein
The Hudson Chapter of the Pack Medical
Foundation, with special thanks to Mr.
Rudolph J. DeAngelo.

The author is deeply indebted to the above for their support, without which this volume could not have been produced.

Finally, we are most indebted to Appleton-Century-Crofts and especially to Mr. Robert E. McGrath and Ms. Holly Reid for their patience and industry in the multitude of editorial tasks in the preparation and production of this book.

MALIGNANT MELANOMA

CONTENTS

		Contributors	xv
Pa		One ENERAL CONSIDERATIONS	
	1.	A Historical Introduction Irving M. Ariel	3
	2.	Theories Regarding the Etiology of Malignant Melanoma Irving M. Ariel	9
	3.	Antiquity, Incidence, and Epidemiology of Moles and Malignant Melanoma Irving M. Ariel	33
	4.	The Pathology of Cutaneous Melanocytic Lesions Marianne Wolff	47
	5.	Moles and Malignant Melanomas of the Preadolescent Child Irving M. Ariel	87
	6.	Tumor Thickness as a Guide to Treatment in Cutaneous Melanoma Alexander Breslow and Glenn W. Geelhoed.	109
	7.	Biologic Regression with Disappearance of Malignant Melanoma Irving M. Ariel	119
	8.	Immunity in Malignant Melanoma Myron Arlen, Ariel Hollinshead, and Joseph Scherrer	129

xii MALIGNANT MELANOMA

9.	Exploitable Physiological Characteristics Associated with Malignant Melanoma Growth Vernon Riley, Darrel H. Spackman, Mary Anne Fitzmaurice, and Phillip W. Banda	143
	Principles of Clinical Evaluation and Treatment of Malignant Melanoma Irving M. Ariel	173
11.	Labelled Chloroquine Analogs in the Diagnosis and Treatment of Ocular and Dermal Melanomas William Beierwaltes and Satinder P. Gill	207
	The Lymphatic Spread of Melanoma and the Effects of Metastases and Surgery upon Lymphatic Dynamics Irving M. Ariel	219
13.	Treatment of Malignant Melanoma by Endolymphatic Therapy John M. Edwards	237
14.	Amelanotic Malignant Melanomas Irving M. Ariel	259
15.	Chemotherapy of Malignant Melanoma Irving M. Ariel	265
	Primary Cutaneous Melanoma: A Report from the Queensland Melanoma Project Neville C. Davis, G. Roderick McLeod, Graeme L. Beardmore, John H. Little, Redmond L. Quinn, and John Holt	281
	Two ALIGNANT MELANOMAS SPECIFIC ANATOMIC SITES	
17.	Melanoma of the Head and Neck Ronald C. Hamaker and John Conley	291

MALIGNANT MELANOMA

30.	Malignant Melanoma Involving the Central Nervous System	
	Irving M. Ariel	513
31.	Metastatic Malignant Melanoma to the Lungs: Principles of Surgical Treatment and Results	
	Irving M. Ariel	519
	Index	523

GENERAL CONSIDERATIONS